A Study of Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma

Nivolumab in Advanced Hodgkin’s Lymphoma | NEJMПодробнее

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphomaПодробнее

Seven-year OS analysis from ECHELON-1: brentuximab vedotin + AVD versus ABVD in Hodgkin lymphomaПодробнее

Neha Mehta-Shah, MD, Weighs in on SWOG 1826 Data, Implications at 2023 ASCO Annual MeetingПодробнее

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphomaПодробнее

Brentuximab vedotin plus chemotherapy prior to ASCT in R/R Hodgkin lymphomaПодробнее

An updated analysis of ECHELON-1: 1L brentuximab vedotin + chemotherapy in stage III/IV classical HLПодробнее

SWOG S1826: nivolumab+AVD vs brentuximab vedotin+AVD for advanced stage Hodgkin lymphomaПодробнее

Novel agents for the treatment of Hodgkin lymphoma: brentuximab vedotin and nivolumabПодробнее

Brentuximab vedotin: current status and future considerations for this agent in HL treatmentПодробнее

Five year update of ECHELON-1 for classical Hodgkin lymphomaПодробнее

Research Builds On Positive ECHELON-1 Study in Hodgkin LymphomaПодробнее

Real-world data on brentuximab vedotin with chemotherapy in Hodgkin lymphomaПодробнее

Christopher Yasenchak, MD, on 1st line brentuximab vedotin + nivolumab in Hodgkin’s lymphomaПодробнее

Long-Term Efficacy and Safety of Brentuximab Vedotin in Hodgkin Lymphoma PatientsПодробнее

Brentuximab Vedotin Adds Benefit to A+AVD Therapy in cHLПодробнее

Follow-Up Data Reaffirms Brentuximab Vedotin’s Efficacy in Treating Late-Stage Hodgkin LymphomaПодробнее

5-year follow-up of ECHELON-1: brentuximab plus AVD versus ABVD in Hodgkin lymphomaПодробнее

Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trialПодробнее

Updates from the ECHELON-1 studyПодробнее